IGFBPL1 (C-5): sc-398875



The Power to Question

BACKGROUND

IGFBPL1 (Insulin-like growth factor-binding protein-like 1) is a secreted IGF (Insulin-like growth factor) binding protein that is known to contain an Ig-like C2-type (immunoglobulin-like) domain, an IGFBP N-terminal domain and a Kazal-like domain. IGF-binding proteins characteristically act to extend the half-life of IGFs and may influence the growth promoting effects of the IGFs. The interaction of IGFBPs with IGFs can affect cell surface receptors, specifically, IGFBPs may enhance or decrease a cells Insulin sensitivity. IGFBPL1 has been found to be down-regulated in multiple tumors and thus may be a likely tumor suppressor candidate. Highly expressed in both brain and testis, IGFBPL1 is found at lower levels in the prostate, bladder and lung.

REFERENCES

- 1. Dupont, J. and Holzenberger, M. 2003. Biology of Insulin-like growth factors in development. Birth Defects Res. C Embryo Today 69: 257-271.
- Cai, Z., et al. 2005. Identification of a novel Insulin-like growth factor binding protein gene homologue with tumor suppressor like properties. Biochem. Biophys. Res. Commun. 331: 261-266.
- 3. Siwanowicz, I., et al. 2005. Structural basis for the regulation of Insulinlike growth factors by IGF binding proteins. Structure 13: 155-167.
- Smith, P., et al. 2007. Epigenetic inactivation implies independent functions for Insulin-like growth factor binding protein (IGFBP)-related protein 1 and the related IGFBPL1 in inhibiting breast cancer phenotypes. Clin. Cancer Res. 13: 4061-4068.
- Bradley, L.M., et al. 2008. Role of the Insulin-like growth factor system on an estrogen-dependent cancer phenotype in the MCF-7 human breast cancer cell line. J. Steroid Biochem. Mol. Biol. 109: 185-196.
- 6. Verheus, M., et al. 2010. IGF1, IGFBP1, and IGFBP3 genes and mammographic density: the Multiethnic Cohort. Int. J. Cancer 127: 1115-1123.
- 7. Taverne, C.W., et al. 2010. Common genetic variation of Insulin-like growth factor-binding protein 1 (IGFBP-1), IGFBP-3, and acid labile subunit in relation to serum IGF-I levels and mammographic density. Breast Cancer Res. Treat. 123: 843-855.

CHROMOSOMAL LOCATION

Genetic locus: IGFBPL1 (human) mapping to 9p13.1; lgfbpl1 (mouse) mapping to 4 B1.

SOURCE

IGFBPL1 (C-5) is a mouse monoclonal antibody specific for an epitope mapping between amino acids 45-61 near the N-terminus of IGFBPL1 of mouse origin.

PRODUCT

Each vial contains 200 μg IgM kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-398875 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% stabilizer protein).

APPLICATIONS

IGFBPL1 (C-5) is recommended for detection of IGFBPL1 of mouse, rat and human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for IGFBPL1 siRNA (h): sc-92508, IGFBPL1 siRNA (m): sc-146181, IGFBPL1 shRNA Plasmid (h): sc-92508-SH, IGFBPL1 shRNA Plasmid (m): sc-146181-SH, IGFBPL1 shRNA (h) Lentiviral Particles: sc-92508-V and IGFBPL1 shRNA (m) Lentiviral Particles: sc-146181-V.


Molecular Weight of IGFBPL1: 29 kDa.


Positive Controls: mouse testis extract: sc-2405, BC_3H1 cell lysate: sc-2299 or F9 cell lysate: sc-2245.


RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz MarkerTM Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein L-Agarose: sc-2336 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use m-lgG κ BP-FITC: sc-516140 or m-lgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850.

DATA







IGFBPL1 (C-5): sc-398875. Western blot analysis of IGFBPL1 expression in SH-SY5Y (**A**) and C2C12 (**B**) whole cell lysates

SELECT PRODUCT CITATIONS

1. Butti, E., et al. 2022. Neural precursor cells tune striatal connectivity through the release of IGFBPL1. Nat. Commun. 13: 7579.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.